Cibinqo
Janus Kinase (JAK) inhibitors are targeted medicines that reduce inflammation by blocking the activity of Janus kinase enzymes, which play an important role in cytokine signalling and immune-system regulation. These medicines interfere with the JAK-STAT signalling pathway, helping reduce abnormal immune responses and inflammatory activity. Depending on their selectivity, they inhibit JAK1, JAK2, JAK3, or TYK2. Examples include tofacitinib, baricitinib, upadacitinib, ruxolitinib, fedratinib, and deucravacitinib. JAK inhibitors are used in selected autoimmune, inflammatory, and haematological conditions.